Pharma & Biotech

The stock has more than doubled since late May, but the coming weeks will determine whether that momentum is sustainable...

Investors are being presented with two sharply conflicting narratives on Kuros Biosciences. The Swiss biotech firm reported a blistering 72%...

Medtronic is shedding complexity. After spinning off its diabetes division, the medical-device giant now operates three core pillars — cardiovascular,...

Outlook Therapeutics enters a high-stakes July with two pivotal events that will shape its future. On the 16th, shareholders must...

Two legal milestones are converging on Bayer within weeks, and the market is holding its breath. By the end of...

The German biotech group BioNTech is sending two very different signals to the market at once. Its management is busy...

The countdown has begun for Outlook Therapeutics, with the U.S. Food and Drug Administration setting a binding decision date of...

Bayer shares vaulted 4.6% to €37.51 on Thursday, hitting a monthly high as investors placed their bets on a single...

A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up...

The Danish pharmaceutical heavyweight arrived at the American Diabetes Association congress in New Orleans armed with a double dose of...